Viking Therapeutics, Inc. (vktx)
VKTX Valuation
| P/E (trailing) | N/A |
| P/E (forward) | -9.46 |
| EV/EBITDA | N/A |
| Price/Sales | N/A |
| Price/Book | 11.90 |
| Market cap | $4.86B |
Start Free — open VKTX in Vest Terminal
Access live data, filings, ownership, and analysis for Viking Therapeutics, Inc..
Viking Therapeutics, Inc. FAQ
What does Viking Therapeutics, Inc. (VKTX) do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone…
What is VKTX's P/E ratio?
Viking Therapeutics, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does VKTX pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is VKTX in?
Viking Therapeutics, Inc. is classified in Healthcare (Biotechnology) on NCM.
What is VKTX's market capitalization?
Approximate market cap: $4.86B.
What are the main risks for VKTX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of VKTX?
Potential positives include moderate leverage (debt/equity 1.00), price near 52-week highs — positive price momentum on public markets.
Where can I get analyst estimates for VKTX?
Public analyst price targets and consensus for Viking Therapeutics, Inc. are on the free /stocks/vktx/estimates page. Deeper estimate history and models are available in Vest Terminal.